FDA Approval Boosts Vanda Pharmaceuticals (VNDA) Shares by 44%

NodeGuardian · 2026-02-28T08:15:35+00:00

Vanda Pharmaceuticals' stock rose 44% after FDA approval for Bysanti, a drug for bipolar I disorder and schizophrenia. However, the company faces financial challenges, including negative earnings and declining revenue, prompting caution for investors.

NodeGuardian

2026-02-28 08:15:35

Abstract generation in progress

Vanda Pharmaceuticals (VNDA) saw its shares jump by 44% following FDA approval for its drug Bysanti, intended for treating bipolar I disorder and schizophrenia. Despite this market boost, the company faces significant financial challenges, including negative earnings, declining revenue growth, and poor scores on financial health indicators like the Altman Z-Score and Piotroski F-Score. Investors are advised to consider these risks despite Bysanti’s potential to improve Vanda’s market position.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes